-
Something wrong with this record ?
Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology
M. Holubová, L. Hrubá, A. Popelová, M. Bencze, V. Pražienková, S. Gengler, H. Kratochvílová, M. Haluzík, B. Železná, J. Kuneš, C. Hölscher, L. Maletínská,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Alzheimer Disease drug therapy metabolism pathology MeSH
- Amyloid beta-Peptides metabolism MeSH
- Plaque, Amyloid drug therapy metabolism pathology MeSH
- Amyloidosis drug therapy metabolism pathology MeSH
- Gliosis drug therapy metabolism pathology MeSH
- Hippocampus drug effects metabolism pathology MeSH
- Prolactin-Releasing Hormone analogs & derivatives MeSH
- Humans MeSH
- Liraglutide pharmacology MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice, Transgenic MeSH
- Random Allocation MeSH
- Neurogenesis drug effects MeSH
- Neuroprotective Agents pharmacology MeSH
- tau Proteins metabolism MeSH
- Inflammation drug therapy metabolism pathology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon-like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm11-PrRP31, an anorexigenic and glucose-lowering analog of prolactin-releasing peptide, in a mouse model of AD-like Tau pathology, THY-Tau22 mice. Here, we demonstrate the neuroprotective effects of palm11-PrRP31 in double transgenic APP/PS1 mice, a model of AD-like β-amyloid (Aβ) pathology. The 7-8-month-old APP/PS1 male mice were subcutaneously injected with liraglutide or palm11-PrRP31 for 2 months. Both the liraglutide and palm11-PrRP31 treatments reduced the Aβ plaque load in the hippocampus. Palm11-PrRP31 also significantly reduced hippocampal microgliosis, consistent with our observations of a reduced Aβ plaque load, and reduced cortical astrocytosis, similar to the treatment with liraglutide. Palm11-PrRP31 also tended to increase neurogenesis, as indicated by the number of doublecortin-positive cells in the hippocampus. After the treatment with both anorexigenic compounds, we observed a significant decrease in Tau phosphorylation at Thr231, one of the first epitopes phosphorylated in AD. This effect was probably caused by elevated activity of protein phosphatase 2A subunit C, the main Tau phosphatase. Both liraglutide and palm11-PrRP31 reduced the levels of caspase 3, which has multiple roles in the pathogenesis of AD. Palm11-PrRP31 increased protein levels of the pre-synaptic marker synaptophysin, suggesting that palm11-PrRP31 might help preserve synapses. These results indicate that palm11-PrRP31 has promising potential for the treatment of neurodegenerative diseases.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012155
- 003
- CZ-PrNML
- 005
- 20210614150808.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuropharm.2018.11.002 $2 doi
- 035 __
- $a (PubMed)30428311
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Holubová, Martina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.
- 245 10
- $a Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology / $c M. Holubová, L. Hrubá, A. Popelová, M. Bencze, V. Pražienková, S. Gengler, H. Kratochvílová, M. Haluzík, B. Železná, J. Kuneš, C. Hölscher, L. Maletínská,
- 520 9_
- $a Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon-like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm11-PrRP31, an anorexigenic and glucose-lowering analog of prolactin-releasing peptide, in a mouse model of AD-like Tau pathology, THY-Tau22 mice. Here, we demonstrate the neuroprotective effects of palm11-PrRP31 in double transgenic APP/PS1 mice, a model of AD-like β-amyloid (Aβ) pathology. The 7-8-month-old APP/PS1 male mice were subcutaneously injected with liraglutide or palm11-PrRP31 for 2 months. Both the liraglutide and palm11-PrRP31 treatments reduced the Aβ plaque load in the hippocampus. Palm11-PrRP31 also significantly reduced hippocampal microgliosis, consistent with our observations of a reduced Aβ plaque load, and reduced cortical astrocytosis, similar to the treatment with liraglutide. Palm11-PrRP31 also tended to increase neurogenesis, as indicated by the number of doublecortin-positive cells in the hippocampus. After the treatment with both anorexigenic compounds, we observed a significant decrease in Tau phosphorylation at Thr231, one of the first epitopes phosphorylated in AD. This effect was probably caused by elevated activity of protein phosphatase 2A subunit C, the main Tau phosphatase. Both liraglutide and palm11-PrRP31 reduced the levels of caspase 3, which has multiple roles in the pathogenesis of AD. Palm11-PrRP31 increased protein levels of the pre-synaptic marker synaptophysin, suggesting that palm11-PrRP31 might help preserve synapses. These results indicate that palm11-PrRP31 has promising potential for the treatment of neurodegenerative diseases.
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x metabolismus $x patologie $7 D000544
- 650 _2
- $a amyloidní beta-protein $x metabolismus $7 D016229
- 650 _2
- $a amyloidóza $x farmakoterapie $x metabolismus $x patologie $7 D000686
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a glióza $x farmakoterapie $x metabolismus $x patologie $7 D005911
- 650 _2
- $a hipokampus $x účinky léků $x metabolismus $x patologie $7 D006624
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x farmakoterapie $x metabolismus $x patologie $7 D007249
- 650 _2
- $a liraglutid $x farmakologie $7 D000069450
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši transgenní $7 D008822
- 650 _2
- $a neurogeneze $x účinky léků $7 D055495
- 650 _2
- $a neuroprotektivní látky $x farmakologie $7 D018696
- 650 _2
- $a amyloidní plaky $x farmakoterapie $x metabolismus $x patologie $7 D058225
- 650 _2
- $a hormon uvolňující prolaktin $x analogy a deriváty $7 D056690
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a proteiny tau $x metabolismus $7 D016875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hrubá, Lucie $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.
- 700 1_
- $a Popelová, Andrea $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.
- 700 1_
- $a Bencze, Michal, $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic; Institute of Physiology of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic. $d 1986- $7 av2016924515
- 700 1_
- $a Pražienková, Veronika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.
- 700 1_
- $a Gengler, Simon $u Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster, LA1 4YW, United Kingdom.
- 700 1_
- $a Kratochvílová, Helena $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21, Prague 4, Czech Republic; Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Haluzík, Martin $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21, Prague 4, Czech Republic; Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.
- 700 1_
- $a Kuneš, Jaroslav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic; Institute of Physiology of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic.
- 700 1_
- $a Hölscher, Christian $u Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster, LA1 4YW, United Kingdom.
- 700 1_
- $a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic. Electronic address: maletin@uochb.cas.cz.
- 773 0_
- $w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 144, č. - (2019), s. 377-387
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30428311 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20210614150808 $b ABA008
- 999 __
- $a ok $b bmc $g 1391465 $s 1050460
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 144 $c - $d 377-387 $e 20181111 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
- LZP __
- $a Pubmed-20190405
